News headlines about DURECT (NASDAQ:DRRX) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DURECT earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.5509064768571 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of DURECT (NASDAQ DRRX) traded up $0.01 on Tuesday, reaching $1.02. The company had a trading volume of 576,800 shares, compared to its average volume of 711,467. DURECT has a 1 year low of $0.74 and a 1 year high of $2.17. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46.
DURECT (NASDAQ:DRRX) last issued its quarterly earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.09. The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. DURECT had a negative return on equity of 419.65% and a negative net margin of 62.57%. research analysts anticipate that DURECT will post -0.14 EPS for the current year.
DRRX has been the subject of several analyst reports. Stifel Nicolaus downgraded DURECT from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. HC Wainwright reaffirmed a “hold” rating on shares of DURECT in a research report on Thursday, November 2nd. ValuEngine raised DURECT from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Finally, Laidlaw decreased their target price on DURECT from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, October 20th.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact DURECT (DRRX) Share Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-durect-drrx-share-price.html.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.